Search results for "Tumor Hypoxia"

showing 10 items of 56 documents

Using the r package spatstat to assess inhibitory effects of microregional hypoxia on the infiltration of cancers of the head and neck region by cyto…

2021

Simple Summary Progress in the field of in situ proteomics allows for the simultaneous detection of multiple biomarkers within one cancer tissue specimen. As a result, biological hypotheses previously only assessable ex vivo can now be studied in human cancer tissue. However, methods for objective analysis have so far been lacking behind. In this study, we established a free, objective, and entirely open-source-based method for the analysis of multiplexed immunofluorescence specimens. This will gain further importance with the availability of more advanced multiplexing methods in the future. Abstract (1) Background: The immune system has physiological antitumor activity, which is partially …

0301 basic medicineCancer ResearchOpen-sourcespatial analysisCellBiologyArticle03 medical and health sciences0302 clinical medicineImmune systemmedicineCytotoxic T cellCancer immune evasionHead and neck cancerHypoxiacancer immune evasionRC254-282open-sourceTumor hypoxiaMultichannel im-munofluorescencehypoxiaHead and neck cancerRSpatial analysisNeoplasms. Tumors. Oncology. Including cancer and carcinogensHypoxia (medical)medicine.diseaseCTL*030104 developmental biologymedicine.anatomical_structureOncologymultichannel immunofluorescence030220 oncology & carcinogenesisCancer researchhead and neck cancermedicine.symptomInfiltration (medical)
researchProduct

Distinct Activities of Glycolytic Enzymes Identify Chronic Lymphocytic Leukemia Patients with a more Aggressive Course and Resistance to Chemo-Immuno…

2018

A higher capacity to grow under hypoxic conditions can lead to a more aggressive behavior of tumor cells. Determining tumor activity under hypoxia may identify chronic lymphocytic leukemia (CLL) with aggressive clinical course and predict response to chemo-immunotherapy (CIT). A metabolic score was generated by determining pyruvate kinase and lactate dehydrogenase, key enzymes of glycolysis, ex vivo in primary CLL samples under normoxic and hypoxic conditions. This score was further correlated with clinical endpoints and response to CIT in 96 CLL patients. 45 patients were classified as metabolic high risk (HR), 51 as low risk (LR). Treatment-free survival (TFS) was significantly shorter in…

0301 basic medicineOncologyMaleChronic lymphocytic leukemiaHigh-risklcsh:Medicinechemistry.chemical_compoundRisk FactorsClinical endpointGlycolysisAged 80 and overlcsh:R5-920Hazard ratioGeneral MedicineMiddle AgedPrognosisFemaleImmunotherapymedicine.symptomIGHV@lcsh:Medicine (General)GlycolysisResearch PaperAdultmedicine.medical_specialtyLDHGeneral Biochemistry Genetics and Molecular BiologyDisease-Free Survival03 medical and health sciencesLactate dehydrogenaseInternal medicinemedicineBiomarkers TumorHumansPK M2AgedProportional Hazards Modelsbusiness.industrylcsh:RHypoxia (medical)medicine.diseaseLeukemia Lymphocytic Chronic B-Cell030104 developmental biologyMetabolismchemistryMutationTumor HypoxiabusinessEx vivoCLLEBioMedicine
researchProduct

Modulating tumor hypoxia by nanomedicine for effective cancer therapy

2016

Hypoxia, a characteristic feature of tumors, is indispensable to tumor angiogenesis, metastasis, and multi drug resistance. Hypoxic avascular regions, deeply embedded inside the tumors significantly hinder delivery of therapeutic agents. The low oxygen tension results in resistance to the current applied anti-cancer therapeutics including radiotherapy, chemotherapy, and photodynamic therapy, the efficacy of which is firmly tied to the level of tumor oxygen supply. However, emerging data indicate that nanocarriers/nanodrugs can offer substantial benefits to improve the efficacy of current therapeutics, through modulation of tumor hypoxia. This review aims to introduce the most recent advance…

0301 basic medicinePhysiologymedicine.medical_treatmentClinical BiochemistryPhotodynamic therapy02 engineering and technologyPharmacologyBiologyMetastasis03 medical and health sciencesNeoplasmsmedicineHumansDrug CarriersNeovascularization PathologicTumor hypoxiaCell BiologyTumor OxygenationHypoxia (medical)021001 nanoscience & nanotechnologymedicine.diseaseCell HypoxiaNanostructuresOxygenRadiation therapyNanomedicine030104 developmental biologyTumor HypoxiaNanomedicinemedicine.symptomNanocarriers0210 nano-technologyJournal of Cellular Physiology
researchProduct

Lack of correlation between expression of HIF-1alpha protein and oxygenation status in identical tissue areas of squamous cell carcinomas of the uter…

2004

Abstract Hypoxia inducible factor-1α (HIF-1α) has been proposed as a candidate endogenous marker of tumor hypoxia and as a molecular mediator of hypoxia-driven malignant progression and acquired treatment resistance. In this study, HIF-1α expression in 68 biopsies of oxygenation measurement tracks from squamous cell carcinomas of the uterine cervix of 38 patients was assessed. Expression of HIF-1α was commonly found to increase as a function of distance from microvessels, at the center of tumor cell aggregations, and in the vicinity of necrotic areas. However, there was no correlation of HIF-1α expression with median oxygen tension (oxygen partial pressure; pO2) and hypoxic fractions (hypox…

AdultCancer ResearchPathologymedicine.medical_specialtyPartial PressureCellUterine Cervical NeoplasmsEndogenyBiologyGene expressionmedicineHumansAgedNeoplasm StagingCell NucleusTumor hypoxiaOxygenationHypoxia (medical)Middle AgedHypoxia-Inducible Factor 1 alpha SubunitCell HypoxiaOxygen tensionOxygenmedicine.anatomical_structureOncologyEpidermoid carcinomaCarcinoma Squamous CellFemalemedicine.symptomTranscription FactorsCancer research
researchProduct

Tumor hypoxia in pelvic recurrences of cervical cancer.

1998

We have previously demonstrated in primary cancer of the uterine cervix that tumor hypoxia, as determined polarographically, is strongly associated with clinical malignant progression of the disease. Having applied a similar methodological approach to investigate loco-regional relapses, we found a pronounced shift to more hypoxic oxygenation profiles in the recurrent tumors than in the primary tumors. Median pO2 values in 53 pelvic recurrences were significantly lower than the median pO2 values of 117 primary tumors of comparable sizes (7.1 +/- 1.1 mmHg vs. 12.1 +/- 1.0 mmHg, p = 0.0013). The differences in tumor oxygenation between primary and recurrent tumors mirrored the differences in t…

AdultCancer ResearchPathologymedicine.medical_specialtyPartial PressureUrologyUterine Cervical NeoplasmsDiseaseAdenocarcinomaCarcinoma AdenosquamousmedicineHumansAgedPelvic NeoplasmsCervical cancerTumor hypoxiabusiness.industryOxygenationPelvic cavityHypoxia (medical)Tumor OxygenationMiddle Agedmedicine.diseaseOxygenmedicine.anatomical_structureOncologyCohortCarcinoma Squamous CellFemalemedicine.symptomNeoplasm Recurrence LocalbusinessPolarographyInternational journal of cancer
researchProduct

Tumor oxygenation: a new predictive parameter in locally advanced cancer of the uterine cervix.

1993

Abstract Experimental evidence suggests that hypoxia may increase the malignant potential and reduce the sensitivity toward nonsurgical treatment modalities in solid rodent tumors. However, the importance of tumor hypoxia in human malignancies is still uncertain. We have developed a clinically applicable standardized procedure for the determination of intratumoral p O 2 in advanced cervical cancers by use of a computerized polarographic needle electrode histograph. To evaluate the significance of tumor oxygenation as a new oncologic parameter we initiated an open prospective clinical trial at the University of Mainz Medical Center in June 1989. Until October 1992 50 patients with advanced c…

AdultPathologymedicine.medical_specialtymedicine.medical_treatmentBrachytherapyUrologyUterine Cervical NeoplasmsMedicineHumansProspective StudiesElectrodesAgedChemotherapyTumor hypoxiabusiness.industryProportional hazards modelObstetrics and GynecologyOxygenationTumor OxygenationHypoxia (medical)Middle AgedPrognosisCombined Modality TherapyCell HypoxiaRadiation therapyClinical trialOxygenTreatment OutcomeOncologyRegression AnalysisFemalemedicine.symptomRadioisotope TeletherapybusinessGynecologic oncology
researchProduct

Oxygenation Status of Gynecologic Tumors: What is the Optimal Hemoglobin Level?

2002

Tumor hypoxia has been linked to the development of treatment resistance, tumor progression, and poor prognosis. Since anemia is a major causative factor for the development of hypoxia, the association between blood hemoglobin concentration (cHb) and tumor oxygenation was examined in this study.Pretreatment O(2) tension (pO(2)) measurements were performed in 59 primary carcinomas of the uterine cervix in which a stringent histopathologic examination of the electrode tracks was mandatory in order to exclude measurements in necrotic, stromal or normal cervical tissue. In addition, pO(2) readings in twelve primary cancers and 17 local recurrences of vulvar cancers were included in this study. …

Adultmedicine.medical_specialtyPathologyAnemiaUterine Cervical NeoplasmsCervix UteriGastroenterologyVulvaOxygen ConsumptionInternal medicineCarcinomamedicineHumansRadiology Nuclear Medicine and imagingAgedNeoplasm StagingVulvar NeoplasmsTumor hypoxiabusiness.industryMiddle AgedTumor OxygenationVulvar cancerHypoxia (medical)Prognosismedicine.diseaseCell HypoxiaTreatment OutcomeOncologyTumor progressionCarcinoma Squamous CellHemoglobinometryFemaleHemoglobinemiamedicine.symptombusinessStrahlentherapie und Onkologie
researchProduct

Glucose metabolism of malignant cells is not regulated by transketolase-like (TKTL)-1.

2010

An isoenzyme of transketolase, transketolase-like (TKTL)-1, has been hypothesized to play a pivotal role in the pathophysiology of malignant tumors. Available data are based on the detection of the putative TKTL-1 protein with one particular mouse monoclonal anti-TKTL-1 antibody, clone JFC12T10. In this study it was demonstrated that a) JFC12T10 detects multiple unspecific bands in Western blots, b) a 75-kDa band hitherto referred to as TKTL-1 corresponds to a nuclear protein and c) immunohistochemical detection of TKTL-1 in benign leiomyomas yields an expression pattern identical to that found in a variety of malignant tumors. In RT-PCR assays, using three different primer pairs for transk…

Cancer ResearchBlotting WesternClone (cell biology)TransketolaseBiologyIsozymeGene Expression Regulation EnzymologicMiceCell Line TumorNeoplasmsAnimalsHumansNuclear proteinTumor hypoxiaOncogeneLeiomyomaAntibodies MonoclonalCell cycleGene Expression Regulation NeoplasticGlucoseOncologyBiochemistryMonoclonalUterine NeoplasmsCancer researchFemaleTransketolaseHeLa CellsInternational journal of oncology
researchProduct

Tumor Hypoxia: Causative Factors, Compensatory Mechanisms, and Cellular Response

2004

Abstract Learning Objectives After completing this course, the reader will be able to: Explain the effect of hypoxia on resistance to treatment. Describe the causes of tumor hypoxia. Characterize cellular response to hypoxia. Access and take the CME test online and receive 1 hour of AMA PRA category 1 credit at CME.TheOncologist.com Hypoxia is a characteristic feature of locally advanced solid tumors resulting from an imbalance between oxygen (O2) supply and consumption. Major causative factors of tumor hypoxia are abnormal structure and function of the microvessels supplying the tumor, increased diffusion distances between the nutritive blood vessels and the tumor cells, and reduced O2 tra…

Cancer ResearchCell SurvivalAnemiamedicine.medical_treatmentPhotodynamic therapyDiseaseNeoplasmsmedicineHumansNeovascularization PathologicTumor hypoxiabusiness.industryAnemiaTumor OxygenationHypoxia (medical)medicine.diseaseAdaptation PhysiologicalCell HypoxiaOxygenRadiation therapyCell Transformation NeoplasticOncologyDrug Resistance NeoplasmImmunologyDisease ProgressionCancer researchHemoglobinmedicine.symptombusinessThe Oncologist
researchProduct

Treatment Resistance of Solid Tumors

2001

Hypoxia is a characteristic property of locally advanced solid tumors, resulting from an imbalance between the supply and consumption of oxygen. Major pathogenetic mechanisms for the development of hypoxia are (1) structural and functional abnormalities of the tumor microvasculature, (2) increased diffusion distances, and (3) tumor-associated and therapy-induced anemia. The oxygenation status is independent of clinical tumor size, stage, grade, and histopathological type, but is affected by the hemoglobin level. Hypoxia is intensified in anemic patients, especially in tumors with low perfusion rates. Hypoxia and anemia (most probably via worsening of tumor hypoxia) can lead to therapeutic p…

Cancer ResearchChemotherapymedicine.medical_specialtyPathologyHematologyTumor hypoxiaAnemiamedicine.medical_treatmentHematologyGeneral MedicineTumor OxygenationHypoxia (medical)Biologymedicine.diseaseRadiation therapyOncologyInternal medicinemedicineCancer researchHemoglobinmedicine.symptomMedical Oncology
researchProduct